急性难治性白血病细胞对化疗药物的体外敏感度实验  

Drug Sensitivity of Acute Refractory Leukemia Cells to Chemotherapeutic Agents

作　　者：田怀平[1] 卜书红[1] 李方[1] 杨镜明[2] 

机构地区：[1]上海第二医科大学附属新华医院药剂科,200092 [2]上海第二医科大学附属新华医院血液科,200092

出　　处：《医药导报》2005年第8期667-669,共3页Herald of Medicine

摘　　要：目的测定急性难治性白血病细胞对13种化疗药物的体外敏感性,探讨急性难治性白血病细胞的体外药敏特点。方法取急性难治性白血病患者骨髓标本37份,分离白血病细胞制成细胞悬液,将13种常见化疗药物以MTT法进行体外药敏试验,测定各药物对白血病细胞的抑制率。结果依托泊苷(VP-16)和阿糖胞苷(Ara-C)对急性淋巴细胞白血病(ALL)和急性非淋巴细胞白血病(ANLL)细胞的平均抑制率可达到体外敏感。柔红霉素(DNR)、表柔比星(EPI)、吡柔比星(THP)、顺铂(DDP)和丝裂霉素(MMC)对以上两种类型的白血病细胞的平均抑制率均达不到体外敏感。替尼泊苷(VM-26)和VP-16对ALL细胞的抑制率高于ANLL细胞;米托蒽醌(MIT)对ANLL细胞的抑制率高于ALL细胞。结论急性难治性白血病普遍可考虑含VP-16和Ara-C的化疗方案;ALL选用含VM-26和VP-16的化疗方案较佳,ANLL可选用含MIT的化疗方案。Objective To study the drug sensitivity of acute refractory leukemia cells to 13 chemotherapeutic agents in vitro. Methods 37 bone marrow specimens from patients with acute refractory leukemia were collected from which leukemia cells were separated for the preparation of leukemic cell suspensions .The drug sensitivity of the leukemic cells to 13 chemotherapeutic agents was assayed with the MTT methods and the rates of inhibition of these agents on the different leukemic cells were determined. Results Acute nonlymphocytic leukemia (ANLL) cells and acute lymphocytic leukemia (ALL) cells were sensitive to etoposida (VP-16) and cylosine arabinoside(Ara-C) but not to daunorubicin(DNP),epirubicin(EPI),pirarubicin(THP),cisplatin(DDP) and mytomycin(MMC).The rate of inhibition of teniposide(VM-26) and etoposide(VP-16) on ALL cells was higher that on ANLL cells .In contrast ,the rate of inhibition of mitoxantrone(MIT) on ANLL cells was higher than that on ALL cells. Conclusion In general, acute refractory leukemia should be submitted to a chemotherapeutic plan containing VP-16 and Ara-c. ALL could better be treated with a chemotherapeutic plan containing VM-26 and VR-16 while ANLL should be treated with a chemotherapeutic plan containing MIT.

关 键 词：白血病 急性 难治性 白血病细胞 药敏试验 

分 类 号：R979.1[医药卫生—药品] R733.71[医药卫生—药学]